CD95/Fas and metastatic disease: What does not kill you makes you stronger

被引:32
|
作者
Guegan, Jean Philippe [1 ,2 ]
Ginestier, Christophe [3 ]
Charafe-Jauffret, Emmanuelle [3 ]
Ducret, Thomas [4 ,6 ]
Quignard, Jean-Francois [4 ,6 ]
Vacher, Pierre [4 ,5 ]
Legembre, Patrick [1 ,2 ]
机构
[1] Equipe Ligue Canc, CLCC Eugene Marquis, Rennes, France
[2] Univ Rennes, INSERM U1242, Rennes, France
[3] Aix Marseille Univ, Inst Paoli Calmettes, Epithelial Stem Cells & Canc Lab, Inserm,CNRS,CRCM, Marseille, France
[4] Univ Bordeaux, Bordeaux, France
[5] INSERM U1218, Bordeaux, France
[6] INSERM U1045, Ctr Rech Cardio Thorac Bordeaux, Bordeaux, France
关键词
Apoptosis; Calcium; Cytoskeleton; Migration; TNF; NF-KAPPA-B; CANCER STEM-CELLS; TO-MESENCHYMAL TRANSITION; FAS-LIGAND; ENDOPLASMIC-RETICULUM; SURFACE ANTIGEN; RECEPTOR SUPERFAMILY; MONOCLONAL-ANTIBODY; AUTOIMMUNE-DISEASE; SIGNALING PATHWAY;
D O I
10.1016/j.semcancer.2019.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD95 (also known as Fas) is the prototype of death receptors; however, evidence suggests that this receptor mainly implements non-apoptotic signaling pathways such as NF-KB, MAPK, and PI3K that are involved in cell migration, differentiation, survival, and cytokine secretion. At least two different forms of CD95 L exist. The multi-aggregated transmembrane ligand (m-CD95 L) is cleaved by metalloproteases to release a homotrimeric soluble ligand (s-CD95 L). Unlike m-CD95 L, the interaction between s-CD95 L and its receptor CD95 fails to trigger apoptosis, but instead promotes calcium-dependent cell migration, which contributes to the accumulation of inflammatory Th17 cells in damaged organs of lupus patients and favors cancer cell invasiveness. Novel inhibitors targeting the pro-inflammatory roles of CD95/CD95 L may provide attractive therapeutic options for patients with chronic inflammatory disorders or cancer. This review discusses the roles of the CD95/CD95 L pair in cell migration and metastasis.
引用
收藏
页码:121 / 131
页数:11
相关论文
共 14 条
  • [1] The dual role of a yeast metacaspase: What doesn't kill you makes you stronger
    Hill, Sandra Malmgren
    Nystrom, Thomas
    BIOESSAYS, 2015, 37 (05) : 525 - 531
  • [2] Role of Fas (CD95) in tubulointerstitial disease induced by unilateral ureteric obstruction
    Hughes, J
    Johnson, RJ
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 277 (01) : F26 - F32
  • [3] The complement system in the pathogenesis and progression of kidney diseases: What doesn't kill you makes you older
    Stea, Emma Diletta
    D'Ettorre, Giuseppina
    Mitrotti, Adele
    Gesualdo, Loreto
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 22 - 31
  • [4] Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis
    Terheyden, P
    Siedel, C
    Merkel, A
    Kämpgen, E
    Bröcker, EB
    Becker, JC
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (06) : 899 - 902
  • [5] Fas/APO-1/CD95 in health and autoimmune disease: thymic and peripheral aspects
    Moulian, N
    Berrih-Aknin, S
    SEMINARS IN IMMUNOLOGY, 1998, 10 (06) : 449 - 456
  • [6] Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
    delaMonte, SM
    Sohn, YK
    Wands, JR
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 (01) : 73 - 83
  • [7] Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
    K Yamana
    V Bilim
    N Hara
    T Kasahara
    T Itoi
    R Maruyama
    T Nishiyama
    K Takahashi
    Y Tomita
    British Journal of Cancer, 2005, 93 : 544 - 551
  • [8] Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
    Yamana, K
    Bilim, V
    Hara, N
    Kasahara, T
    Itoi, T
    Maruyama, R
    Nishiyama, T
    Takahashi, K
    Tomita, Y
    BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 544 - 551
  • [9] Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression
    Aries, SP
    Schaaf, B
    Muller, C
    Dennin, RH
    Dalhoff, K
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (12): : 591 - 593
  • [10] CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease
    Smith, KGC
    Strasser, A
    Vaux, DL
    EMBO JOURNAL, 1996, 15 (19) : 5167 - 5176